Population Exposure-Response Modeling of the Effects of Apomorphine Sublingual Film on QTc in Patients With Parkinson’s Disease and “OFF” Episodes
Objective: To characterize the relationship between plasma apomorphine concentrations and QTc (QT interval corrected for heart rate) in patients with Parkinson’s disease (PD) and “OFF”…The Efficacy and Safety of Subcutaneous Apomorphine in Patients with Parkinson’s Disease: A Meta-Analysis Randomized Controlled Trials
Objective: The objective of this study to evaluate the efficacy and safety of subcutaneous apomorphine for patients with Parkinson’s disease (PD). Background: Subcutaneous apomorphine has…The prevalence of ICBs in patients treated with apomorphine infusion: a retrospective analysis
Objective: To assess the prevalence of impulsive compulsive behaviours (ICBs) in Parkinson’s disease who donated their brains and used apomorphine infusion in life. Background: Impulsive…Motor Responses to Apomorphine Sublingual Film Compared With Levodopa in Patients With Parkinson’s Disease and “OFF” Episodes: Post Hoc Analysis From a Phase 3 Study
Objective: To compare time to onset and magnitude of motor improvement following administration of apomorphine sublingual film (APL-130277; APL) vs levodopa in patients with Parkinson’s…Treatment of Levodopa Dose Failure with Subcutaneous Apomorphine Injection
Objective: We evaluated a subset of patients who were enrolled in the AMIMPAKT trial of sc apomorphine injection to treat morning akinesia (see reference) who…Patient’s Choice of Device-Based Treatments in Parkinson’s Disease
Objective: Deep brain stimulation of subtalamic nucleus (STN-DBS), subcutaneous apomorphine infusion (APO) and levodopa-carbidopa intestinal gel infusion (DUO) is routinely used in patients with advanced…Atypical Response to Apomorphine in a Patient with Multiple System Atrophy
Objective: Multiple system atrophy (MSA) is a sporadic neurodegenerative disease clinically characterized by cerebellar signs, parkinsonism and autonomic dysfunction. MSA is classified into two sub-types;…Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from the Phase 3 double-blind, placebo-controlled trial
Objective: To evaluate the efficacy of APL-130277 (APL) in a double-blind, placebo-controlled trial. Background: OFF episodes are a common, disabling complication of Parkinson’s disease (PD)…Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from a Phase 3 double-blind, placebo-controlled trial
Objective: To evaluate the safety of APL-130277 (APL) in the double-blind, placebo-controlled trial Titration Phase (TP) and Maintenance Phase (MP). Background: OFF episodes are a…Pharmaeconomic study of the treatment of advanced Parkinson’s disease.
Objective: Conduct a comparative pharmacoeconomic analysis of the use of subcutaneous apomorphine infusion pump (SAIP), continuous levodopa/carbidopa duodenal infusión (LDI) and deep brain stimulation (DBS). Background:…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- Next Page »